Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease

摘要: The role of proton pump inhibitor in the treatment laryngopharygneal reflux disease (LPRD) has been advocated, but there few reports dealing with large population based on time-related efficacy rabeprazole. It was designed to assess rabeprazole and evaluate which symptoms or findings varied significantly as medication sustained. Multiorgan, open-label cohort, prospective observational study designed. We identified 1,142 patients LPRD, enrolled 455 patients, who participated fully this survey follow-up observation for 12 weeks. Reflux symptom index (RSI) finding score (RFS) were used therapeutic efficacy. These parameters evaluated at 4th, 8th, 12th weeks, respectively. Valid rate explain improved proportion after medication. most common a globus sense throat. Posterior commissure hypertrophy frequently encountered laryngoscopic finding. Female complained heartburn chest pain more than did male (P < 0.001), whereas showed ventricular obliteration erythematous changes female 0.001). By RSI evaluation, scores gradually declined. Each item every visit Total RFS decreased progressively weeks similar results seen when individually examined. falling by 50% increased continued. This trend seemed be significant Side effects therapy minimal. Despite some constraints an study, appeared improve LPRD signs. Prolonged least 3 months may beneficial patients. Long-term require further evaluation.